Xencor's basic earnings per share (Basic EPS) for the
three
months ended in Dec. 2024 was $-0.62.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.63.
Xencor's EPS (Diluted) for the
three
months ended in Dec. 2024 was $-0.62.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.63.
Xencor's EPS without NRI for the
three
months ended in Dec. 2024 was $-0.20.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -2.86.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Xencor's highest 3-Year average EPS without NRI Growth Rate was 8.10% per year. The lowest was -42.80% per year. And the median was -16.40% per year.
Xencor EPS (Basic) Historical Data
The historical data trend for Xencor's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Xencor's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor (NAS:XNCR) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Xencor EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Xencor's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XNCR has been successfully added to your 